To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Inclusion Criteria:

• Group 1 only: Biopsy-proven participants with relapsed or refractory NHL of DLBCL,FL or MZL.

• Groups 3, 4a and 5 only: Biopsy-proven participants with relapsed or refractoryDLBCL.

• Groups 2 and 6 only: Biopsy-proven participants with DLBCL and another selectlymphoid neoplasms.

• Participants must have at least 1 bi-dimensionally measurable lesion.

• ECOG performance status of 0 to 2.

• Participants with protocol defined laboratory criteria at screening as defined inthe protocol.

• Group 1 only:

Received at least 1 previous systemic therapy line for the treatment of NHL. At least 1 previous therapy line must have included a CD20-targeted therapy (eg, RTX).

• Groups 2, 3, 4a and 6 only:

Received at least 1, but no more than 3, previous systemic therapy lines for the treatment of DLBCL. At least 1 previous therapy line must have included a CD20-targeted therapy (eg, RTX).

• Group 5 only: Participants must have:

1. Untreated DLBCL.

2. Ann Arbor Stage III to IV.

3. IPI status of 3 to 5 or age-adjusted IPI 2-3 (in Group 5 only).

4. Appropriate candidate for R-CHOP.

5. LVEF of ≥ 50%, assessed by echocardiography.

• Willingness to avoid pregnancy or fathering children.

• In the opinion of investigator, the participant must:

1. Not have a history of noncompliance in relation to medical regimens or beconsidered potentially unreliable and/or uncooperative.

2. Be able to understand the reason for complying with the special conditions ofthe pregnancy prevention risk management plan and give written acknowledgementof this.

Exclusion Criteria:

• Any other histological type of lymphoma.

• History of prior non-hematologic malignancy.

• Congestive heart failure requiring use of ongoing maintenance therapy forlife-threatening ventricular arrhythmias.

• Participants with known positive test result for hepatitis C, and hepatitis B.

• Known seropositive for or history of active viral infection with HIV.

• Known active bacterial, viral, fungal, mycobacterial, or other infection atscreening.

• Known CNS lymphoma involvement - present or past medical history.

• History or evidence of clinically significant cardiovascular, CNS and/or othersystemic disease that would in the investigator's opinion preclude participation inthe study or compromise the participant's ability to give informed consent.

• History or evidence of rare hereditary problems of galactose intolerance, Lapplactase deficiency or glucose-galactose malabsorption.

• History or evidence of interstitial lung disease.

• Vaccination with live vaccine within 21 days prior to study treatment (Note:throughout the study treatment period and at least 6 months after end of treatment,vaccination with live vaccines should be avoided).

• Major surgery within up to 30 days prior to signing the ICF, unless the participantis recovered at the time of signing the ICF.

• Any anticancer and/or investigational therapy within 14 days prior to the start ofCycle 1.

• Groups 2, 3, 4a, 5 and 6 only: Gastrointestinal abnormalities including theinability to take oral study treatment, requiring IV alimentation, or prior surgicalprocedure affecting absorption.

• Pregnancy or lactation.

• Groups 2, 3, 5 and 6 only: Participants who have history of deep venousthrombosis/embolism, threatening thromboembolism, stroke or known thrombophilia orare at a high risk for a thromboembolic event in the opinion of the investigator andwho are not willing/able to take venous thromboembolic event prophylaxis during theentire treatment period if required

• Group 4a only: Use or expected use during the study of any restricted medications,including potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the date of study treatment administration

• Groups 1, 3, 4a and 6 only: Participants who have:

1. Not discontinued CD20-targeted therapy, chemotherapy, radiotherapy,investigational anticancer therapy, or other lymphoma-specific therapy withinthe 14 days prior to Day 1 dosing.

2. In the opinion of the investigator, not recovered sufficiently from the adversetoxic effects of prior therapies.

3. Groups 1, 3 and 4a only: Previous treatment with CD19-targeted therapy (eg,CD19-CAR-T therapies, other CD19 mAbs including bispecific and ADCs).Groups 2 and 6 only: Previous treatment with tafasitamab. Note: Participants inGroups 2 and 6 who have received previous CD19 directed therapy (other thantafasitamab) must have CD19-positive lymphoma confirmed by a biopsy taken aftercompleting the prior CD19-targeted therapy.

4. Groups 2, 3 and 6 only: Been previously treated with IMiDs (eg, thalidomide orLEN).

5. Group 4a only: Been previously treated with selective PI3Kδ or pan-PI3Kinhibitors (eg, idelalisib, copanlisib, duvelisib) and/or Bruton's tyrosinekinase inhibitors (eg, ibrutinib).

6. A history of hypersensitivity to compounds of similar biological or chemicalcomposition to tafasitamab, IMiDs, and/or the excipients contained in the studytreatment formulations (citric acid monohydrate, polysorbate 20, sodium citratedehydrate and trehalose dihydrate).

7. Undergone ASCT within the period ≤ 3 months before the signing of the ICF.Participants who have a more distant history of ASCT must exhibit fullhematological recovery before enrolment into the study.

8. Undergone previous allogenic stem cell transplantation.

9. Concurrent treatment other anticancer or experimental treatments.

• Group 5 only: Participants who have:

1. A history of radiation therapy to ≥ 25% of the bone marrow for other diseasesor history of anthracycline therapy.

2. A history of hypersensitivity or contraindication to any component of R-CHOP,LEN, or compounds of similar biological or chemical composition as tafasitamaband/or the excipients contained in the study treatment formulations or R-CHOP.

3. Contraindication to any of the individual components of R-CHOP.

4. Any anticancer and/or investigational therapy within 30 days prior to the startof Cycle 1, except for permitted prephase treatment defined below.